ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.96549
-0.04%
Brent Oil
83.895
0.32%
Bitcoin
59,333.69
0.36%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) Noticias

RVNC Revance Therapeutics Inc

3.77
-0.025 (-0.66%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Revance Therapeutics Inc RVNC NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.025 -0.66% 3.77 17:00:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.91 3.655 3.99 3.77 3.795
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202415:05BWRevance to Release First Quarter 2024 Financial Results on..
12/4/202407:00BWRevance to Present New DAXXIFY® Data at the American Academy..
27/3/202415:05BWRevance Reports Inducement Grants Under Nasdaq Listing Rule..
08/3/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:08EDGAR2Form 8-K - Current report
05/3/202416:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202416:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202416:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202415:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202408:25BWRevance Announces Pricing of $100.0 Million Public Offering..
04/3/202405:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202405:37BWRevance Announces Proposed Public Offering of Common Stock
29/2/202415:36EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/2/202415:07EDGAR2Form 8-K - Current report
28/2/202415:05BWRevance Reports Fourth Quarter and Full Year 2023 Financial..
21/2/202407:01BWRevance to Release Fourth Quarter and Full Year 2023..
21/2/202407:00BWRevance to Participate in Upcoming Investor Conferences
14/2/202414:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202415:28EDGAR2Form 8-K - Current report
13/2/202408:39EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202415:04EDGAR2Form 8-K - Current report
02/2/202415:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202407:00BWRevance Receives Permanent J-Code for DAXXIFY® and Announces..
01/2/202407:00BWRevance to Participate in the Guggenheim 6th Annual..
11/1/202405:18IHMARKETNEWSWall Street Highlights: Mastercard’s Financial Rise,..
08/1/202407:01EDGAR2Form 8-K - Current report
08/1/202407:00BWRevance Provides Corporate Update, Preliminary Fourth..
03/1/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202315:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202315:04EDGAR2Form 8-K - Current report
12/12/202304:50IHMARKETNEWSHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic..
14/11/202315:22EDGAR2Form S-3ASR - Automatic shelf registration statement of..
08/11/202315:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:09EDGAR2Form 8-K - Current report
08/11/202315:06BWRevance Reports Third Quarter 2023 Financial Results,..
08/11/202315:05BWRevance Appoints Erica Jordan as Chief Commercial Officer,..
06/11/202307:00BWRevance to Participate in Upcoming Investor Conferences
01/11/202307:00BWRevance to Release Third Quarter 2023 Financial Results on..
26/10/202307:00BWDAXXIFY® Becomes First Facial Injectable to be Named to..
24/10/202315:05EDGAR2Form SC 13D/A - General statement of acquisition of..
19/9/202308:01EDGAR2Form 8-K - Current report
19/9/202308:00BWRevance Provides Corporate Update at Investor Day
07/9/202316:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202315:21EDGAR2Form 144 - Report of proposed sale of securities
05/9/202316:43EDGAR2Form 144 - Report of proposed sale of securities

Su Consulta Reciente

NASDAQ
RVNC
Revance Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados